本文仅供医疗卫生专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
参考文献：
1. 中国抗癌协会淋巴瘤专业委员会,中华医学会血液学分会.中华血液学杂志,2020,41(7):537-544.
2. Xu B, Lin ZJ. Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):983-988. Chinese.
3. Salles G, et al. Clinical Lymphoma Myeloma and Leukemia, 2023, 23: S454-S455. https://www.sciencedirect.com/science/article/abs/pii/S2152265023013630.
4. Lica JJ, et al. Molecules. 2024; 29(17):4280.
5. 2024 ASH abstract 4415. https://ash.confex.com/ash/2024/webprogram/Paper202639.html.
6. Gilles Salles, et al. Blood. 2023;142:3035.
7. Julia E, et al. Future Oncol. 2021 Jun;17(17):2127-2140.
8. Morschhauser F, et al. Lancet Oncol. 2020 Nov;21(11):1433-1442.
9. Raychaudhuri R, et al. Onco Targets Ther. 2022 Feb 27;15:193-199.
10. Ennishi D, et al. Cancer Discov. 2019 Apr;9(4):546-563.
11. Tong KI, et al. Clin Cancer Res. 2021 Oct 1;27(19):5401-5414.
12. Loretta J. Nastoupil, et al. ASH 2023. 4410. https://www.postersessiononline.eu/173580348_eu/congresos/ASH2023/aula/-MON_4410_ASH2023.pdf.
13. 2024 ASH abstract 4792. https://ash.confex.com/ash/2024/webprogram/Paper206011.html.
14. Brach D, et al. Mol Cancer Ther. 2017 Nov;16(11):2586-2597.
15. https://clinicaltrials.gov/study/NCT05994235?intr=tazemetostat&viewType=Table&rank=28.
16. https://clinicaltrials.gov/study/NCT06575686?intr=tazemetostat&viewType=Table&rank=49.
17. https://clinicaltrials.gov/study/NCT05890352?intr=tazemetostat&viewType=Table&rank=54.
18. https://clinicaltrials.gov/study/NCT06242834?intr=tazemetostat&viewType=Table&rank=47.
19. https://clinicaltrials.gov/study/NCT05618366?intr=tazemetostat&viewType=Table&rank=21.
20. https://clinicaltrials.gov/study/NCT05627245?intr=tazemetostat&viewType=Table&rank=50.
【NP-TAZ-24N1447-Valid Until-2026-December】
本资料由和黄医药提供支持。
本资料旨在促进医药信息的沟通和交流，而非广告宣传。
